U.S. markets open in 9 hours 2 minutes

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.31-0.63 (-2.87%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close21.94
Open21.58
Bid19.20 x 1200
Ask23.00 x 800
Day's Range20.87 - 21.76
52 Week Range14.71 - 30.14
Volume689,634
Avg. Volume759,755
Market Cap1.529B
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction
    GlobeNewswire

    Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction

    Top Line Results of METEORIC-HF Expected in Early 2022 Company Plans to Submit NDA in 2H 2021 Based on Positive Results of GALACTIC-HF SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil. METEORIC-HF is d

  • Cytokinetics to Participate in Upcoming Investor Conferences
    GlobeNewswire

    Cytokinetics to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in three virtual fireside chats at the following investor conferences: 42nd Annual Goldman Sachs Healthcare Conference on Wednesday, June 9, 2021 at 3:00 PM EDTJMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 4:00 PM EDTRaymond James Human Health Innovation Conference

  • Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    GlobeNewswire

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2021 it granted stock options to purchase an aggregate of 49,500 shares of common stock to eight new employees whose employment commenced in May 2021 as a material inducement to their employment. The grant was previously approved by the Compensation and Talent Committee of Cytokinetics’ Board of Directors under the company’s Amended and Restated 2004 Equity Inc